Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: LJM who wrote (51)	7/27/2006 4:09:56 PM
From: Mike McFarland	Read Replies (3) \| Respond to of 210

You wonder if Kosan will walk away from their 17-aag, fall back to their epothilone program. Holtzman says they have a better drug, and I have to believe it, well I don't have to, but I want to. The bit about solubility rings true and sounds very plausible, to me. I still have not bought the Chiosis paper Overall, these characteristics propose Hsp90 as an important target of whose inhibition may aim at a wide-range of oncogenic transformations. Several years into Hsp90 research have shed light into the feasibility, but also the limitations, of such an approach. So, what are the limitations? Anybody read the paper?